Literature DB >> 34010360

SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for spillback to New World rodents.

Anna Fagre1, Juliette Lewis1, Miles Eckley1, Shijun Zhan1, Savannah M Rocha2, Nicole R Sexton1, Bradly Burke1, Brian Geiss1, Olve Peersen3, Todd Bass4, Rebekah Kading1, Joel Rovnak1, Gregory D Ebel1, Ronald B Tjalkens2, Tawfik Aboellail1, Tony Schountz1.   

Abstract

Coronavirus disease-19 (COVID-19) emerged in late 2019 in China and rapidly became pandemic. As with other coronaviruses, a preponderance of evidence suggests the virus originated in horseshoe bats (Rhinolophus spp.) and may have infected an intermediate host prior to spillover into humans. A significant concern is that SARS-CoV-2 could become established in secondary reservoir hosts outside of Asia. To assess this potential, we challenged deer mice (Peromyscus maniculatus) with SARS-CoV-2 and found robust virus replication in the upper respiratory tract, lungs and intestines, with detectable viral RNA for up to 21 days in oral swabs and 6 days in lungs. Virus entry into the brain also occurred, likely via gustatory-olfactory-trigeminal pathway with eventual compromise to the blood-brain barrier. Despite this, no conspicuous signs of disease were observed, and no deer mice succumbed to infection. Expression of several innate immune response genes were elevated in the lungs, including IFNα, IFNβ, Cxcl10, Oas2, Tbk1 and Pycard. Elevated CD4 and CD8β expression in the lungs was concomitant with Tbx21, IFNγ and IL-21 expression, suggesting a type I inflammatory immune response. Contact transmission occurred from infected to naive deer mice through two passages, showing sustained natural transmission and localization into the olfactory bulb, recapitulating human neuropathology. In the second deer mouse passage, an insertion of 4 amino acids occurred to fixation in the N-terminal domain of the spike protein that is predicted to form a solvent-accessible loop. Subsequent examination of the source virus from BEI Resources determined the mutation was present at very low levels, demonstrating potent purifying selection for the insert during in vivo passage. Collectively, this work has determined that deer mice are a suitable animal model for the study of SARS-CoV-2 respiratory disease and neuropathogenesis, and that they have the potential to serve as secondary reservoir hosts in North America.

Entities:  

Year:  2021        PMID: 34010360     DOI: 10.1371/journal.ppat.1009585

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  39 in total

1.  Natural Transmission and Experimental Models of SARS CoV-2 Infection in Animals.

Authors:  Jessica C Gomes Noll; Gabriela M do Nascimento; Diego G Diel
Journal:  Comp Med       Date:  2021-10-26       Impact factor: 0.982

2.  Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera.

Authors:  Raveen Rathnasinghe; Sonia Jangra; Chengjin Ye; Anastasija Cupic; Gagandeep Singh; Carles Martínez-Romero; Lubbertus C F Mulder; Thomas Kehrer; Soner Yildiz; Angela Choi; Stephen T Yeung; Ignacio Mena; Virginia Gillespie; Jana De Vrieze; Sadaf Aslam; Daniel Stadlbauer; David A Meekins; Chester D McDowell; Velmurugan Balaraman; Michael J Corley; Juergen A Richt; Bruno G De Geest; Lisa Miorin; Florian Krammer; Luis Martinez-Sobrido; Viviana Simon; Adolfo García-Sastre; Michael Schotsaert
Journal:  Nat Commun       Date:  2022-07-07       Impact factor: 17.694

Review 3.  Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals.

Authors:  David A Meekins; Natasha N Gaudreault; Juergen A Richt
Journal:  Viruses       Date:  2021-10-04       Impact factor: 5.048

4.  Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.

Authors:  James S Terry; Loran Br Anderson; Michael S Scherman; Carley E McAlister; Rushika Perera; Tony Schountz; Brian J Geiss
Journal:  Virology       Date:  2021-02-01       Impact factor: 3.513

Review 5.  Risk assessment of SARS-CoV-2 infection in free-ranging wild animals in Belgium.

Authors:  Myriam Logeot; Axel Mauroy; Etienne Thiry; Nick De Regge; Muriel Vervaeke; Olivier Beck; Valérie De Waele; Thierry Van den Berg
Journal:  Transbound Emerg Dis       Date:  2021-05-26       Impact factor: 4.521

6.  Susceptibility of white-tailed deer (Odocoileus virginianus) to SARS-CoV-2.

Authors:  Mitchell V Palmer; Mathias Martins; Shollie Falkenberg; Alexandra Buckley; Leonardo C Caserta; Patrick K Mitchell; Eric D Cassmann; Alicia Rollins; Nancy C Zylich; Randall W Renshaw; Cassandra Guarino; Bettina Wagner; Kelly Lager; Diego G Diel
Journal:  J Virol       Date:  2021-03-10       Impact factor: 6.549

7.  High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay.

Authors:  Markus H Kainulainen; Eric Bergeron; Payel Chatterjee; Asheley P Chapman; Joo Lee; Asiya Chida; Xiaoling Tang; Rebekah E Wharton; Kristina B Mercer; Marla Petway; Harley M Jenks; Timothy D Flietstra; Amy J Schuh; Panayampalli S Satheshkumar; Jasmine M Chaitram; S Michele Owen; Laura K McMullan; Mike Flint; M G Finn; Jason M Goldstein; Joel M Montgomery; Christina F Spiropoulou
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.996

Review 8.  Furin cleavage sites in the spike proteins of bat and rodent coronaviruses: Implications for virus evolution and zoonotic transfer from rodent species.

Authors:  Alison E Stout; Jean K Millet; Michael J Stanhope; Gary R Whittaker
Journal:  One Health       Date:  2021-06-22

9.  SARS-CoV-2 Reverse Zoonoses to Pumas and Lions, South Africa.

Authors:  Katja Natalie Koeppel; Adriano Mendes; Amy Strydom; Lia Rotherham; Misheck Mulumba; Marietjie Venter
Journal:  Viruses       Date:  2022-01-11       Impact factor: 5.048

Review 10.  Evidence of central nervous system infection and neuroinvasive routes, as well as neurological involvement, in the lethality of SARS-CoV-2 infection.

Authors:  Jia-Mei Liu; Bai-Hong Tan; Shuang Wu; Yue Gui; Jia-Le Suo; Yan-Chao Li
Journal:  J Med Virol       Date:  2020-10-14       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.